Bhagat C I, Langton P, Lewer M, Ching S, Beilby J P
Department of Clinical Biochemistry, PathCentre, Nedlands, Western Australia.
Ann Clin Biochem. 1997 Sep;34 ( Pt 5):511-6. doi: 10.1177/000456329703400503.
Cardiac troponin I (cTnI) has been reported to be a highly specific marker for cardiac injury. We investigated the performance of this assay in patients admitted to a coronary care unit for suspected acute myocardial infarction (AMI), patients with extensive skeletal muscle damage, marathon runners and as a routine diagnostic test over a four week period. cTnI proved to be as sensitive a marker for AMI as creatine kinase/MB isoenzyme (CKMB) in patients admitted to the coronary care unit. In 10 patients with a proven AMI, the cTnI remained elevated from 69 to 183 h with a median time of 127 h. Cardiac troponin I had superior specificity to CKMB in patients with skeletal muscle damage. It was very useful in these patients to confirm or exclude concurrent myocardial damage. In routine diagnostic use, cTnI had greater efficiency than CKMB to classify patients as having an AMI. Consequently cTnI should replace CKMB as a marker for AMI.
心肌肌钙蛋白I（cTnI）据报道是心脏损伤的一种高度特异性标志物。我们研究了该检测方法在因疑似急性心肌梗死（AMI）入住冠心病监护病房的患者、有广泛骨骼肌损伤的患者、马拉松运动员中的表现，并将其作为四周期间的常规诊断检测。在入住冠心病监护病房的患者中，cTnI被证明是与肌酸激酶/MB同工酶（CKMB）一样敏感的AMI标志物。在10例经证实的AMI患者中，cTnI从69小时至183小时持续升高，中位时间为127小时。在骨骼肌损伤患者中，心肌肌钙蛋白I比CKMB具有更高的特异性。这对这些患者确认或排除并发心肌损伤非常有用。在常规诊断应用中，cTnI在将患者分类为患有AMI方面比CKMB更有效。因此，cTnI应取代CKMB作为AMI的标志物。
